Research Study in Patients With Severe Ulcerative Colitis
Launched by FACET BIOTECH · Mar 15, 2002
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
A Phase I, dose-escalation, pilot study designed to obtain safety and tolerability data on visilizumab administered to patients with severe ulcerative colitis that has failed to respond to steroid therapy. Patients who are currently receiving IV corticosteroids, but whose disease has not responded after at least 5 days of this therapy, will be eligible for the study.
Gender
ALL
Eligibility criteria
- • 1. A diagnosis of ulcerative colitis verified by colonoscopy or barium enema performed within 36 months prior to study entry.
- • 2. Active disease despite ongoing treatment with steroids
About Facet Biotech
Facet Biotech is a biopharmaceutical company dedicated to advancing innovative therapies for patients with serious and underserved medical conditions. Focusing on the development of novel treatments, Facet Biotech leverages cutting-edge research and a robust pipeline to address significant unmet needs in various therapeutic areas, including oncology and autoimmune diseases. With a commitment to scientific excellence and patient-centric solutions, the company collaborates with leading academic institutions and industry partners to accelerate drug discovery and development, ultimately aiming to transform patient care and improve outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Los Angeles, California, United States
San Francisco, California, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
New York, New York, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials